A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kebenko, Maxim, Goebeler, Marie-Elisabeth, Wolf, Martin, Hasenburg, Annette, Seggewiss-Bernhardt, Ruth, Ritter, Barbara, Rautenberg, Beate, Atanackovic, Djordje, Kratzer, Andrea, Rottman, James B., Friedrich, Matthias, Vieser, Eva, Elm, Stefanie, Patzak, Ingrid, Wessiepe, Dorothea, Stienen, Sabine, Fiedler, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136859/
https://www.ncbi.nlm.nih.gov/pubmed/30221040
http://dx.doi.org/10.1080/2162402X.2018.1450710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136859/
https://www.ncbi.nlm.nih.gov/pubmed/30221040
http://dx.doi.org/10.1080/2162402X.2018.1450710

Ejemplares similares